BetterLife Pharma (OTCMKTS:BETRF – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
BetterLife Pharma Price Performance
OTCMKTS:BETRF opened at $0.24 on Thursday. BetterLife Pharma has a one year low of $0.03 and a one year high of $0.33. The business has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.12. The firm has a market capitalization of $40.98 million, a price-to-earnings ratio of -24.09 and a beta of 0.22.
BetterLife Pharma Company Profile
BetterLife Pharma Inc is a Canadian biotechnology company focused on developing novel treatments for mental health and neurological conditions. Its research programs are centered on pharmaceutical compounds derived from or inspired by psychedelic substances, with the goal of creating therapies that may offer therapeutic benefits without the hallucinogenic effects associated with some traditional psychedelics.
The company’s development programs have included BETR-001, a synthetic derivative of lysergic acid diethylamide (LSD) being studied for potential applications in depression and other neuropsychiatric disorders, and BETR-002, an ibogaine-derived compound being investigated for substance-use disorders and related conditions.
Featured Articles
- Five stocks we like better than BetterLife Pharma
- Boeing’s Fighter Victory Opens the Door to Decades of Defense Revenue
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
Receive News & Ratings for BetterLife Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BetterLife Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
